Registry for metastatic breast cancer in Austria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects and documents data on patients with metastatic breast cancer in Austria, aiming to provide a comprehensive overview of the disease's characteristics and treatment outcomes. It includes both prospective and retrospective data collection, focusing on tumor characteristics, medical histories, and treatment sequences. The registry will analyze factors such as median age at metastasis, disease-free survival, and the distribution of metastatic subtypes, ultimately contributing to a better understanding of the disease in the Austrian population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological evidence of breast cancer
* Histological and/or radiological evidence of metastases
* Metastasis within 10 years of registry initiation
* Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Exclusion Criteria:

* Due to the non-interventional design of the registry there are no specific exclusion criteria.

Where it's running

• Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität; Universitätsklinik für Innere Medizin III Salzburg
  Salzburg, State of Salzburg, Austria Recruiting
• AKH Wien; Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie
  Vienna, State of Vienna, Austria Recruiting
• Steiermärkische Krankenanstalten- gesellschaft m. b. H. LKH-Univ. Klinikum Graz; Universitätsklinik für Innere Medizin; Klinische Abteilung für Onkologie
  Graz, Styria, Austria Recruiting
• Landeskrankenhaus - Universitätskliniken Innsbruck; Universitätsklinik für Frauenheilkunde Innsbruck
  Innsbruck, Tyrol, Austria Recruiting
• BKH Kufstein; Innere Medizin: Interne II und onk. Tagesklinik
  Kufstein, Tyrol, Austria Recruiting
• Kepler Universitätsklinikum; Univ.-Klinik für Hämatologie und Internistische Onkologie
  Linz, Upper Austria, Austria Recruiting

Study contacts

• Study coordinator: Daniela Wolkersdorfer
• Email: d.wolkersdorfer@agmt.at
• Phone: +43 662 6404412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• Body composition and outcomes after breast reconstruction

  This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07546331

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• ENLIGHT algorithm to find treatment options for advanced metastatic breast cancer

  This test uses the ENLIGHT algorithm to try to find approved drugs that might work better for adults with triple-negative or endocrine therapy–resistant metastatic breast cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07067138

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Omitting full axillary dissection when breast cancer has spread to armpit nodes

  The trial tests whether removing only the sentinel and known cancerous lymph nodes is as safe as removing many more armpit nodes in people with breast cancer and armpit node involvement.

  Recruiting at 4 sites Karolinska Institutet · Helsinki and 3 other locations · NCT06869629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.